Biologic treatments for systemic rheumatic diseases
Open Access
- 15 February 2008
- journal article
- review article
- Published by Wiley in Oral Diseases
- Vol. 14 (3), 206-216
- https://doi.org/10.1111/j.1601-0825.2008.01440.x
Abstract
Many rheumatologic disorders, most notably Sjögren’s syndrome, are associated with dental complications and in some cases oral diseases may trigger or drive connective tissue disease. During the past three decades the treatment in rheumatology was revolutionized by the introduction of disease‐modifying anti‐rheumatic drugs. Advances in our understanding of the pathogenesis of rheumatic diseases have led to the discovery of critical mechanisms of inflammation and autoimmunity and the invention of new target‐specific biologic agents. In this review, we will summarize the current state of biologic therapies in rheumatology and discuss the implications of these on oral health and disease.Keywords
This publication has 128 references indexed in Scilit:
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Annals Of The Rheumatic Diseases, 2007
- Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnnals Of The Rheumatic Diseases, 2007
- Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2007
- Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trialAnnals Of The Rheumatic Diseases, 2007
- Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialAnnals Of The Rheumatic Diseases, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Correlation of serum B lymphocyte stimulator and 2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2005
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndromeThe Journal of Pathology, 2004
- Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritisJournal of Chronic Diseases, 1978